<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580004</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00158766</org_study_id>
    <nct_id>NCT04580004</nct_id>
  </id_info>
  <brief_title>The Optimization of Medications in Chronic Heart Failure Using a Website</brief_title>
  <official_title>The Optimization of Medications in Chronic Heart Failure Using a Website</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure (HF) is the most common hospital discharge diagnosis among older adults in the&#xD;
      United States. Strikingly, 2 in 5 patients are readmitted within 1-year following their first&#xD;
      HF admission. This results in significant potentially avoidable costs to our already strained&#xD;
      healthcare system since hospitalizations result in 70% of yearly HF management costs. One of&#xD;
      the most common causes of readmission is lack of medication optimization. This study will&#xD;
      determine the effectiveness of a medication optimization website.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a prospective design, 100 patients will be randomized to the intervention or usual care in&#xD;
      a 1:1 fashion. Patients randomized to the intervention will receive an evidence-based&#xD;
      medication recommendation intervention. Outcome measures will be collected at baseline and at&#xD;
      2 weeks post-intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 22, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in medications will be measured by the Evidence Based Medicine Percent Score (EBMPS).</measure>
    <time_frame>Change over 2 weeks</time_frame>
    <description>The Evidence Based Medicine Percent Score (EBMPS) is calculated by the medications and doses the patient is taking (in points) divided by the total eligible medications based on the evidence (in points).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Medication Optimization Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the medication optimization group will receive an evidence-based medication recommendation intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the control group will receive the same intervention, delayed 2 weeks after the intervention group. During those initial 2 weeks they will act as a control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Med Optimization Arm</intervention_name>
    <description>An evidence-based medication recommendation website that is provided to the patients.</description>
    <arm_group_label>Medication Optimization Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  left ventricular ejection fraction (LVEF) &lt;/= 40%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  active cancer with a life expectancy less than 12 months&#xD;
&#xD;
          -  hospice&#xD;
&#xD;
          -  chronic inotropic therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P Dorsch, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Michael Dorsch</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Pharmacy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

